Christine JD - Neurogene CFO President
| NGNE Stock | 22.64 0.56 2.54% |
President
Christine JD is CFO President of Neurogene
| Age | 46 |
| Address | 535 W 24th Street, New York, NY, United States, 10011 |
| Phone | (855) 508-3568 |
| Web | https://www.neurogene.com |
Neurogene Management Efficiency
The company has return on total asset (ROA) of (0.3236) % which means that it has lost $0.3236 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4134) %, meaning that it created substantial loss on money invested by shareholders. Neurogene's management efficiency ratios could be used to measure how well Neurogene manages its routine affairs as well as how well it operates its assets and liabilities. As of December 23, 2024, Return On Tangible Assets is expected to decline to -0.17. In addition to that, Return On Capital Employed is expected to decline to -0.29. As of December 23, 2024, Total Assets is expected to decline to about 155.8 M. In addition to that, Non Current Assets Total is expected to decline to about 20.2 MSimilar Executives
| Showing other executives | PRESIDENT Age | ||
| Scott Carter | Franklin Street Properties | 47 | |
| Derek Klutch | MI Homes | 60 | |
| Michael Walsh | Boston Properties | 57 | |
| John Demeritt | Franklin Street Properties | 64 | |
| Douglas Linde | Boston Properties | 60 | |
| Eriel Anchondo | Franklin Street Properties | 46 | |
| Michael Ray | Western Digital | 56 | |
| Bryan Koop | Boston Properties | 65 | |
| Peter Otteni | Boston Properties | N/A | |
| Robert Pester | Boston Properties | 63 | |
| John Powers | Boston Properties | 73 | |
| Kevin Brown | MI Homes | N/A | |
| Leo Daley | Franklin Street Properties | N/A | |
| William Friend | Franklin Street Properties | N/A | |
| Rell Lafargue | Reservoir Media | 51 | |
| Michael LaBelle | Boston Properties | 60 | |
| Frank Burt | Boston Properties | 61 | |
| Kazuhiro Kashio | Casio Computer Co | 57 | |
| Jake Stroman | Boston Properties | N/A | |
| Peter Johnston | Boston Properties | 61 | |
| John Donahue | Franklin Street Properties | 57 | |
Management Performance
| Return On Equity | -0.41 | ||||
| Return On Asset | -0.32 |
Neurogene Leadership Team
Elected by the shareholders, the Neurogene's board of directors comprises two types of representatives: Neurogene inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Neurogene. The board's role is to monitor Neurogene's management team and ensure that shareholders' interests are well served. Neurogene's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Neurogene's outside directors are responsible for providing unbiased perspectives on the board's policies.
| MD MBA, Senior Development | ||
| Rachel McMinn, Executive Founder | ||
| Christine JD, CFO President | ||
| Effie MD, Senior Research | ||
| Donna JD, Senior Counsel | ||
| CPI FAAP, Quality Affairs | ||
| Ricardo Jimenez, Senior Operations | ||
| Julie MD, Chief Officer | ||
| Stuart Cobb, Chief Officer | ||
| Arvind Sreedharan, Senior Operations |
Neurogene Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Neurogene a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.41 | ||||
| Return On Asset | -0.32 | ||||
| Operating Margin | (21.77) % | ||||
| Current Valuation | 211.85 M | ||||
| Shares Outstanding | 14.83 M | ||||
| Shares Owned By Insiders | 10.69 % | ||||
| Shares Owned By Institutions | 89.31 % | ||||
| Number Of Shares Shorted | 1.17 M | ||||
| Price To Book | 2.45 X | ||||
| Price To Sales | 363.58 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Neurogene is a strong investment it is important to analyze Neurogene's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Neurogene's future performance. For an informed investment choice regarding Neurogene Stock, refer to the following important reports:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurogene. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Neurogene Stock refer to our How to Trade Neurogene Stock guide.You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurogene. If investors know Neurogene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurogene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.66) | Revenue Per Share 0.106 | Return On Assets (0.32) | Return On Equity (0.41) |
The market value of Neurogene is measured differently than its book value, which is the value of Neurogene that is recorded on the company's balance sheet. Investors also form their own opinion of Neurogene's value that differs from its market value or its book value, called intrinsic value, which is Neurogene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurogene's market value can be influenced by many factors that don't directly affect Neurogene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neurogene's value and its price as these two are different measures arrived at by different means. Investors typically determine if Neurogene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurogene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.